ST45177901 is a CC chemokine receptor 4 ( CCR4 ) antagonist. The combination of ST45177901 and Sorafenib effectively inhibits the chemotaxis of Treg cells via the CCL22/CCL17-CCR4 signaling pathway, thereby significantly suppressing the growth and metastasis of tumor cells. ST45177901 is applicable to liver cancer research [1].
In Vivo, ST45177901 exhibits effects similar to those of C-021 (C-021, when combined with Sorafenib, effectively inhibits hepatocellular carcinoma growth) in mice[1].
References:
[1]. Yang, et al. Application of sorafenib combined with CCR4 antagonist for restraining cancer growth and transfer. CN106421796A. China. 2016-11-02.
In Vivo, ST45177901 exhibits effects similar to those of C-021 (C-021, when combined with Sorafenib, effectively inhibits hepatocellular carcinoma growth) in mice[1].
References:
[1]. Yang, et al. Application of sorafenib combined with CCR4 antagonist for restraining cancer growth and transfer. CN106421796A. China. 2016-11-02.